Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus TACE in HCC with PVTT
NCT04127396Phase 4Unknown
- Sponsor
- Beijing Ditan Hospital
- Start
- Sep 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) and Portal vein tumor thrombus (PVTT), sponsored by Beijing Ditan Hospital. Primary endpoint: Time to Progression at 18 months. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)Portal vein tumor thrombus (PVTT)
Beyond the preview
Go deeper on NCT04127396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04127396.